The lack of any approved therapy to target the PI3K/AKT/mTOR pathway in pediatric and adult patients who carry germline PTEN mutations known to significantly increase their lifetime risk for cancer [11] remains an area of unmet medical need. This evidence concerns the gene PIK3CA and cancer.